Patent · US Active

Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations

US9206481B2 · kind B2 · utility

8Cited by

3References

5Claims

0Family size

Assignee

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. · US

Inventors

Shiv Srivastava · Potomac, US
Albert Dobi · Columbia, US
Taduru Sreenath · Germantown, US
Gyorgy Petrovics · Bethesda, US
Chen Sun · Beijing, CN

Key dates

Filing date	Apr 10, 2008
Grant date	Dec 8, 2015
Priority date	—
Expiry date	Oct 17, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Alterations in ERG gene expression can be observed in patients with prostate cancer. Specific ERG isoforms are associated with, or involved in, prostate cancer. Compositions comprising these isoforms provide therapeutic benefit and can be used in methods of detecting, diagnosing, prognosing, and treating prostate cancer. These compositions provide biomarkers for detecting the expression of combinations of the PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG genes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.